Open figure viewer
Significance
Demand for the company's type 2 diabetes treatment, Ozempic, and its higher-dose version, Wegovy, has surged since November when the US Food and Drug Administration (FDA) approved Wegovy for weight loss. Sales of prescription weight-loss drugs will surge, with Eli Lilly's antidiabetic, Mounjaro, also approved for weight loss and rivals Amgen and Pfizer racing to follow.
Impacts
Adherence and weight-gain-recurrence rates, said by some physicians to be low and high, respectively, will be key to the drugs' prospects.
Bifurcation of the drug class between diabetes and weight loss uses would sustain markets for medical equipment such as insulin pumps.
Weight loss drugs will further raise employers' costs for employee health insurance.
© Oxford Analytica 2024. All rights reserved. This content contains general information about geopolitical, macroeconomic and social developments or (where stated) other matters. It does not contain advice or recommendations that may be relied on. Where links to external websites are provided, this does not indicate that Oxford Analytica or Emerald agree with, endorse or have checked for accuracy the contents of said sites.
2024
You do not currently have access to this content.
